Olarif Ophthalmic Solution

Olopatadine inhibits the release of histamine from the mast cell and is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Olopatadine has no effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Olopatadine was shown to have low systemic exposure after topical administration.

Olopatadine Nasal Spray contains 0.6% w/v Olopatadine (base) in a nonsterile aqueous solution with pH of approximately 3.7. After initial priming (5 sprays), each metered spray from the nasal applicator delivers 100 microliters of the aqueous solution containing 665 mcg of olopatadine Hydrochloride, which is equivalent to 600 mcg of Olopatadine (base). Olopatadine Nasal Spray also contains benzalkonium chloride (0.01%), dibasic sodium phosphate, edetate disodium, sodium chloride, hydrochloric acid and/or sodium hydroxide (to adjust pH), and purified water.

Eye Drops-

• 0.1%: One drop in each affected eye two times per day at an interval of 6 to 8 hours.
• 0.2%: One drop in the affected eye once a day.
• 0.7%: One drop in each affected eye once a day.

Nasal Spray-

• Adults and Adolescents 12 years of age and older: Two sprays per nostril twice daily.
• Children 6 to 11 years of age: One spray per nostril twice daily.
• Administer Olopatadine Nasal Spray by the intranasal route only.

Tablet-

• Adults: Take 1 tablet (5 mg of the active ingredient) at a time, twice daily, in the morning and before going to bed. The dosage may be adjusted according to the disease, age or symptoms.
• Children 7 years old or over: Take 1 tablet (5 mg) at a time, twice daily, in the morning and before going to bed.
• If you miss a dose, take a dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and follow your regular dosing schedule. You should never take two doses at one time. Do not stop taking this medicine unless your doctor instructs you to do so.

How to use the Nasal Spray-

• Shake the bottle gently and remove the dust cover.
• Hold the spray with your forefinger and middle finger on either side of the nozzle and your thumb underneath the bottle. Press down until a fine spray appears. If using for the first time or if you have not used it for a week or more, press the nasal applicator several times until a fine moist comes out from the container.
• Gently blow the nose to clear the nostrils.
• Close one nostril and carefully insert the nasal applicator into the open nostril. Tilt your head forward slightly and keep the spray upright. Breathe in through your nose and while breathing in, press the white-collar of nasal applicator firmly down once to release a spray.
• Breathe out through your mouth.
• Repeat the above steps in the same/ other nostril for consecutive doses.

Cleaning: The nasal spray should be cleaned at least once a week. The procedures are as follows-

• Remove the dust cover.
• Gently pull off the nasal applicator.
• Wash the applicator and dust cover in warm water.
• Shake off the excess water and leave to dry in a normal place. Avoid to apply additional heat.
• Gently push the applicator back on the top of the bottle and re-fix the dust cover.

Specific drug interaction studies have not been conducted with Olarif ophthalmic solution.

It is contraindicated in persons with a known hypersensitivity to any component of this product. Olopatadine 5 mg tablet is not recommended for use if you are allergic to it. Inform your doctor about your current medications and pre-existing medical conditions to make sure this medicine is safe for you.

Rarely headaches have been reported. Other adverse effects: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion.

Olopatadine was found not to be teratogenic in rats and rabbits. There are, however, no adequate and well controlled studies in pregnant women. This drug should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when Olopatadine is administered to a nursing mother.

Patients should be advised not to wear a contact lens if their eye is red. Olarif ophthalmic solution should not be used to treat contact lens related irritation. Benzalkonium Chloride, preservative of Patadin, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least 10 minutes after instillation of Patadin eye drops before they insert their contact lenses. The treatment should be discontinued in the presence of an allergic reaction.

Before initial use, Olarif Nasal Spray by releasing 5 sprays or until a fine mist appears. When Olarif Nasal Spray has not been used for more than 7 days, re-prime by releasing 2 sprays. Avoid spraying Olarif Nasal Spray into the eyes. Patients should be informed to avoid spraying Olarif Nasal Spray in their eyes.

Olonex Tablet should be used as prescribed by your doctor. Take it at the same time every day to maintain a constant level of this medicine in your body. Avoid taking more than the recommended dose. Do not stop taking this medicine without consulting your doctor, as your symptoms may reoccur.

Geriatric Use: No overall differences in safety or effectiveness have been observed betweents.

There is no information on Olarif overdose. However, excessive use of any medication can have serious consequences. If you suspect an overdose, seek medical attention without delay.

Ophthalmic Non-Steroid drugs

Store at room temperature and protect from light. It is desirable that the contents should not be used more than one month after first opening of the bottle.